All > Fatty Liver > Knoxville

100 mg MGL-3196 for Non-Alcoholic Fatty Liver Disease (NAFLD)

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Non-Alcoholic Fatty Liver Disease (NAFLD)MGL-3196 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether the drug MGL-3196 can help treat NASH and prevent it from progressing to more serious liver diseases.

Eligible Conditions
  • Non-Alcoholic Fatty Liver Disease (NAFLD)

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

1
Miricorilant Dose Escalation
1
OA-235i (4-30 mg)
1
Cotadutide

Study Objectives

4 Primary · 3 Secondary · Reporting Duration: up to 54 months

24 weeks
LDL Cholesterol Lipoproteins
52 weeks
Week 52 Dual Primary Objectives: To determine the effect of 80 or 100 mg MGL-3196 vs matching placebo on liver biopsy (NASH CRN score) at Week 52 compared with Baseline
Week 24
To determine the effect of once-daily, oral administration of MGL-3196 80 or 100 mg versus matching placebo on the percent change from Baseline at 24 weeks in low-density lipoprotein cholesterol (LDL-C)
Week 52
To evaluate the effect of MGL-3196 80 mg or 100 mg compared to placebo to achieve NASH resolution on liver histology in non-cirrhotic NASH patients with Stage 1 fibrosis
To evaluate the effect of MGL-3196 80 mg or 100 mg compared to placebo to achieve NASH resolution on liver histology in non-cirrhotic NASH patients with stage 2 or 3 fibrosis
To evaluate the effect of MGL-3196 80 mg or 100 mg compared to placebo to achieve improvement in fibrosis on liver histology in non-cirrhotic NASH patients with stage 2 or 3 fibrosis
Month 54
Composite long-term outcome events composed of all-cause mortality, cirrhosis, and other significant liver-related events
up to 54 months
Month 54 Primary Objective: Time to experiencing an adjudicated Composite Clinical Outcome event (Final Primary Endpoint, at 54 months)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
Miricorilant Dose Escalation
1
OA-235i (4-30 mg)
2
Cotadutide

Trial Design

3 Treatment Groups

100 mg MGL-3196
1 of 3
80 mg MGL-3196
1 of 3
Matching Placebo
1 of 3

Active Control

Non-Treatment Group

2000 Total Participants · 3 Treatment Groups

Primary Treatment: 100 mg MGL-3196 · Has Placebo Group · Phase 3

100 mg MGL-3196
Drug
ActiveComparator Group · 1 Intervention: MGL-3196 · Intervention Types: Drug
Matching Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
80 mg MGL-3196
Drug
ActiveComparator Group · 1 Intervention: MGL-3196 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 54 months

Who is running the clinical trial?

Madrigal Pharmaceuticals, Inc.Lead Sponsor
14 Previous Clinical Trials
3,650 Total Patients Enrolled
Rebecca Taub, MDStudy DirectorMadrigal Pharmaceuticals, Inc.
8 Previous Clinical Trials
2,929 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be willing to participate in the study and provide written informed consent.
You are a male or female adult ≥ 18 years of age.
You have a suspected or confirmed diagnosis of NASH.
Patient has metabolic risk factors and AST > 20 U/L.
You have no steatosis.
You have lobular inflammation (scored 0 to 3).

Who else is applying?

What state do they live in?
Tennessee25.0%
Missouri25.0%
California25.0%
Other25.0%
How old are they?
18 - 65100.0%
What site did they apply to?
Ruane Clinical Research33.3%
Miami Dade Medical Research Institute33.3%
Saint Louis University33.3%
What portion of applicants met pre-screening criteria?
Did not meet criteria25.0%
Met criteria75.0%
Why did patients apply to this trial?
  • "releif and money for study"
How many prior treatments have patients received?
3+100.0%

How responsive is this trial?

Average response time
  • < 1 Day
Most responsive sites:
  1. Ruane Clinical Research: < 24 hours
Typically responds via
Phone Call100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top